Monash IVF GroupMNIVF 78 EBIT per Share is $0.05 as of Dec. 2025. GuruFocus rates MNIVF with a GF Score™ of 78/100 and a GF Value™ of $0.78. The stock has 8 warning signs investors should review. Among 168 Medical Diagnostics & Research companies, Monash IVF Group ranks better than 54.76% on this metric.
Monash IVF Group's EBIT per Share for the
six
months ended in Dec. 2025 was $0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.05.
During the past 12 months, the average EBIT per Share Growth Rate of Monash IVF Group was 1216.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 15.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Monash IVF Group's EBIT per Share or its related term are showing as below:
MNIVF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -21.5 Med: -10 Max: 15.7
Current: 15.7
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Monash IVF Group was 15.70% per year. The lowest was -21.50% per year. And the median was -10.00% per year.
MNIVF's 3-Year EBIT Growth Rate is ranked better than 54.76% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.75
vs MNIVF: 15.70
Monash IVF Group (OTCPK:MNIVF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Monash IVF Group EBIT per Share Related Terms
Monash IVF Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for Monash IVF Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monash IVF Group (MNIVF) has a EBIT per Share of $0.05 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Monash IVF Group and its competitors. According to the industry distribution chart, Monash IVF Group ranks #76 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 45.2%.
Is Monash IVF Group's EBIT per Share too high?
Monash IVF Group's current EBIT per Share is $0.05. The Medical Diagnostics & Research industry median EBIT per Share is 12.75. Monash IVF Group's value of $0.05 is 99.6% below this industry median. Based on the distribution chart, Monash IVF Group ranks #76 out of 168 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Monash IVF Group has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Monash IVF Group's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Monash IVF Group ranks #76 out of 168 companies for EBIT per Share. This puts Monash IVF Group in the upper half of its industry. The industry median EBIT per Share is 12.75. Monash IVF Group's value of $0.05 is 99.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monash IVF Group's current EBIT per Share of $0.05 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Monash IVF Group and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monash IVF Group's current EBIT per Share is $0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monash IVF Group stock overvalued right now?
Monash IVF Group (MNIVF) has a current EBIT per Share of $0.05. The stock's GF Value™ is $0.78, compared to a current price of $0.40 — trading 48.7% below its estimated fair value. The current EBIT per Share is $0.05 and 99.6% below the Medical Diagnostics & Research industry median of 12.75. Monash IVF Group's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Monash IVF Group (MNIVF), the current EBIT per Share is $0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monash IVF Group (MNIVF) Overvalued in 2026?
Based on GuruFocus' analysis, Monash IVF Group stock appears to be undervalued.
The current stock price of $0.40 is trading 48.7% below its estimated GF Value™ of $0.78.
Key valuation signals for MNIVF:
EBIT per Share: $0.05
GF Value™: $0.78 vs. price of $0.40 (48.7% below fair value)
Industry Position: 99.6% below the Medical Diagnostics & Research median (#76 of 168)
No single metric tells the full story. See the MNIVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monash IVF Group Ltd is a provider of fertility services, specializing in Assisted Reproductive Services (ARS) and genetic care across Australia and South East Asia. The Group operates two main segments: Australia IVF and Ultrasound, which offer ARS, ultrasound, and related women's health services, and International IVF, which provides assisted reproductive care in South East Asia. The majority of revenue is generated from the Australian segment through its brands such as Fertility Solutions, KL Fertility, Monash IVF, Repromed, and others.
78GF Score
Get the complete analysis for MNIVF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNIVF has been successfully added to your 
